Overview

Safety, Tolerability, and Pharmacokinetics of Raltegravir (MK-0518) in Healthy Japanese Male Participants (MK-0518-851)

Status:
Completed
Trial end date:
2018-10-23
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate safety, tolerability, and pharmacokinetics of a single 1200-mg dose of raltegravir (MK-0518, ISENTRESS®) in healthy Japanese male participants.
Phase:
Phase 4
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Raltegravir Potassium